Usual dosing regimens for antiretroviral treatments used for HIV.
HIV medication contraindications and drug interactions comparison chart.
Healthy HIV-positive patients with anal cancer are treated with standard chemoradiotherapy, but whether this patient population experiences worse outcomes or more severe toxic effects was previously unknown.
View a regimen chart with detailed drug information for treating anal cancer, including 5-fluorouracil + mitomycin + radiotherapy or 5FU + cisplatin.
Women with HIV are more likely to experience progressive cervical changes, according to a study.
View a treatment regimen chart for AIDS-related B-cell lymphoma, with detailed information based on condition (ie, Burkitt lyphoma, Castleman's Disease).
Overall survival for patients with advanced non-small cell lung cancer was greater for those with EGFR mutations versus those with KRAS mutations.
HIV-infected patients with cancer may face a higher cancer-specific mortality compared to those without HIV.
Autologous hematopoietic stem cell transplantation (AHCT) should be considered standard of care for HIV-associated lymphoma.
[Cancer Control] Castleman disease is a lesser seen lymphoproliferative disorder, which is characterized as either localized or multicentric, with differing treatments typically utilized for each type.
Proportion of cancer patients undergoing HIV testing varies by demographic and health-related factors, by state.
[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). Etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) discussed.
[Biomark Cancer] Biomarkers can provide great opportunities in the management of the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer.
Higher proportion of patients with HIV don't receive treatment for lymphomas, lung, prostate, or colorectal cancers.
Researchers are developing a synthetic version of HIP metabolite to treat Kaposi sarcoma.
The start of the "sun-worshipping season" is a good time to review the basics of basal cell and squamous cell carcinomas.
Study results indicate that reactivation of the hepatitis C virus (HCV) in HIV-positive patients with lymphoma does not worsen survival outcomes.
CHICAGO, IL—Siltuximab, a novel chimeric anti−interleukin-6 monoclonal antibody, is active in patients with multicentric Castleman's disease (MCD) who have had insufficient response to or failed previous therapies.
Janssen Biotech announced that the FDA has approved Sylvant (siltuximab) for the treatment of patients with multicentric Castleman's disease (MCD) who are HIV negative and HHV-8 negative.
This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines for children through age 18 years.
Nanopharmaceutical formulations might allow newly widespread adoption of old anticancer agents, with reduced toxic effects.
Recommended age groups and medical indications for routine administration of currently licensed vaccines for persons 19 years and older.
RiBVD regimen appears effective in elderly patients with untreated mantle cell lymphoma.
Siltuximab improves symptoms and clinical outcomes for patients with multicentric Castleman's disease, despite a high rate of drug discontinuation due to toxicities, according to data presented at ASH 2013.
Performing early stem cell transplants in patients with aggressive non-Hodgkin lymphoma does not improve overall survival.
Standard and low-dose EPOCH-R treatment results in high rates of disease-free, overall survival in patients with Burkitt's lymphoma.
Emerging screening technologies and strategies are being added to the cervical cancer prevention arsenal.
Demographic, immunologic, virologic, and histologic shifts occurring, but mortality stable
Although studies are still in their infancy, doctors are using T-cell immunotherapy to attack recurrent leukemic cancer cells, with astonishing results.
Although rare, Castleman disease can occur in patients with Kaposi sarcoma and other cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy